Please login to the form below

Not currently logged in
Email:
Password:

ovarian cancer

This page shows the latest ovarian cancer news and features for those working in and with pharma, biotech and healthcare.

AZ nabs US approval for new leukaemia drug Lumoxiti

AZ nabs US approval for new leukaemia drug Lumoxiti

cancer. However, AZ has two other targeted drugs – PARP inhibitor Lynparza (olaparib) for breast and ovarian cancer and EGFR blocker Tagrisso (osimertinib) – still in the growth phase. ... National Cancer Institute (NCI) in the US, the lead

Latest news

  • New cancer drugs can’t quite plug the revenue hole at AZ New cancer drugs can’t quite plug the revenue hole at AZ

    Ovarian and breast cancer drug Lynparza (olaparib), Tagrisso (osimertinib) for lung cancer and new immuno-oncology therapy Imfinzi (durvalumab) collectively drove oncology sales at the group up 42% to $2.66bn – ... PARP inhibitor Lynparza’s new

  • MaxCyte gets green light for solid tumour cell therapy MaxCyte gets green light for solid tumour cell therapy

    MaxCyte gets green light for solid tumour cell therapy. Its first CAR therapy will be tested in patients with ovarian cancer. ... The trial will test MaxCyte’s first wholly-owned CAR therapy MCY-M11 in patients with relapsed/refractory ovarian cancer

  • AZ and MSD surpass rivals with updated Lynparza data AZ and MSD surpass rivals with updated Lynparza data

    AZ and MSD surpass rivals with updated Lynparza data. Aims for first-line indication in the ovarian cancer setting. ... in the first-line maintenance setting for women with BRCA-mutated ovarian cancer treated with a PARP inhibitor.”.

  • Daily Brief: Keytruda and microbiome synergy, Pfizer's files PARP contender and more Daily Brief: Keytruda and microbiome synergy, Pfizer's files PARP contender and more

    The phase I study will evaluate the benefits in patients who progressed on prior PD-1 inhibitor therapy with renal, bladder, melanoma and non-small cell lung cancer. ... In January, Lynparza became the first of the class to gain approval in breast cancer,

  • NICE backs Tesaro’s Zejula via the CDF NICE backs Tesaro’s Zejula via the CDF

    NICE backs Tesaro’ s Zejula via the CDF. Recommends the drug for second-line use in ovarian cancer patients. ... Although significant progress has been made in the treatment of ovarian cancer, the disease recurs in approximately 85% of women with

More from news
Approximately 35 fully matching, plus 143 partially matching documents found.

Latest Intelligence

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    and ovarian cancer, and some tumours such as pancreatic and prostate cancers have proved resistant to current immunotherapies. ... tumours. Researchers are also investigating whether preventive vaccines could be deployed in people with high-risk cancer

  • The tipping point The tipping point

    In 2016 alone, there were approximately 30 oncology drugs in late stage development for breast cancer, leukaemia, lung cancer and ovarian cancer.

  • AI’s potential in the pharma life cycle AI’s potential in the pharma life cycle

    Proactive intervention. Already AI is being used to identify women whose Twitter posts indicate they may have increased risk of developing two relatively rare diseases: ovarian cancer and cervical cancer.

  • Europe vs the US: New drug product approvals Europe vs the US: New drug product approvals

    Among the noteworthy approvals are Lartruvo (for the treatment of soft tissue sarcoma, approved in the EU and US), Rubraca (for the treatment of ovarian cancer, only approved in the US),

  • Deal Watch May 2016 Deal Watch May 2016

    Prima has partnered its immuno-oncology CVac in ovarian cancer by transferring its CVac related assets, including manufacturing protocols, clinical data, patents and know‐ how plus certain assets e.g. ... 110. CSPC Pharmaceutical/ Watson [Allergan].

More from intelligence
Approximately 0 fully matching, plus 12 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M&F Health

M&F Health is a full service communications agency, dedicated to the health and wellbeing sector. We are an independent amongst...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics